Pacific Biosciences of California, Inc.
General ticker "PACB" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $422.4M (TTM average)
Pacific Biosciences of California, Inc. follows the US Stock Market performance with the rate: 37.9%.
Estimated limits based on current volatility of 5.7%: low 2.27$, high 2.54$
Factors to consider:
- Total employees count: 575 (-27.8%) as of 2024
- US accounted for 48.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Inability to develop and commercialize products, Lack of profitability, Cost reduction challenges, Liquidity and credit risks, Acquisition/divestiture risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.18$, 3.40$]
- 2025-12-31 to 2026-12-31 estimated range: [1.12$, 3.21$]
Financial Metrics affecting the PACB estimates:
- Positive: with PPE of -2.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -39.65 <= 0.33
- Positive: Investing cash flow per share per price, % of 23.86 > -0.66
- Positive: 18.93 < Shareholder equity ratio, % of 40.19 <= 41.86
- Negative: negative Net income
Short-term PACB quotes
Long-term PACB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $128.30MM | $200.52MM | $154.01MM |
| Operating Expenses | $435.50MM | $534.99MM | $628.33MM |
| Operating Income | $-307.20MM | $-334.47MM | $-474.31MM |
| Non-Operating Income | $-7.05MM | $16.31MM | $164.78MM |
| Interest Expense | $14.69MM | $14.34MM | $13.41MM |
| R&D Expense | $193.00MM | $187.17MM | $134.92MM |
| Income(Loss) | $-314.25MM | $-318.16MM | $-309.54MM |
| Taxes | $0.00MM | $-11.42MM | $0.32MM |
| Profit(Loss)* | $-314.25MM | $-306.74MM | $-309.85MM |
| Stockholders Equity | $562.90MM | $701.30MM | $506.59MM |
| Inventory | $50.38MM | $56.68MM | $58.76MM |
| Assets | $1,767.09MM | $1,746.01MM | $1,260.45MM |
| Operating Cash Flow | $-263.21MM | $-259.17MM | $-206.06MM |
| Capital expenditure | $16.93MM | $8.84MM | $6.19MM |
| Investing Cash Flow | $116.08MM | $4.60MM | $124.00MM |
| Financing Cash Flow | $9.62MM | $108.89MM | $-42.99MM |
| Earnings Per Share** | $-1.40 | $-1.21 | $-1.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.